DOJ Sides With Sandoz in SCOTUS Case Leftovers Against Amgen

Drug Industry Daily
The U.S. government sided with Sandoz on the residual claims from the biosimilar manufacturer’s Supreme Court case with Amgen — arguing the federal law outlining the biosimilar approval process should preempt state laws on the topic.

To View This Article:


Subscribe To Drug Industry Daily